Abstract
Tubular cell loss is prominent both in acute and chronic renal failure. Apoptosis and its regulatory mechanisms contribute to cell number regulation in the kidney. The potential role of apoptosis ranges from induction and progression to repair of renal injury. However, therapeutic interest has focused in preventing the apoptotic loss of tubular cells that leads to acute and chronic renal failure. Death ligands and receptors, such as tumor necrosis factor and Fas ligand, proapoptotic and antiapoptotic Bcl2 family members and caspases have all been shown to participate in apoptosis regulation in the course of renal cell injury. Nevertheless, the precise role of these proteins is unclear, and the participation of most known apoptosis regulatory proteins has not been studied. We now review the role of apoptosis in renal injury, the potential molecular targets of therapeutic intervention, the therapeutic weapons to modulate the activity of these targets and the few examples of therapeutic intervention on apoptosis, with emphasis in acute renal failure.
Keywords: Apoptosis, kidney, acute renal failure, Bcl2, death receptor, caspase
Current Medicinal Chemistry
Title: Modulation of Renal Tubular Cell Survival: Where is the Evidence?
Volume: 13 Issue: 4
Author(s): C. Lorz, A. Benito-Martin, P. Justo, A. B. Sanz, M. D. Sanchez-Nino, B. Santamaria, J. Egido and A. Ortiz
Affiliation:
Keywords: Apoptosis, kidney, acute renal failure, Bcl2, death receptor, caspase
Abstract: Tubular cell loss is prominent both in acute and chronic renal failure. Apoptosis and its regulatory mechanisms contribute to cell number regulation in the kidney. The potential role of apoptosis ranges from induction and progression to repair of renal injury. However, therapeutic interest has focused in preventing the apoptotic loss of tubular cells that leads to acute and chronic renal failure. Death ligands and receptors, such as tumor necrosis factor and Fas ligand, proapoptotic and antiapoptotic Bcl2 family members and caspases have all been shown to participate in apoptosis regulation in the course of renal cell injury. Nevertheless, the precise role of these proteins is unclear, and the participation of most known apoptosis regulatory proteins has not been studied. We now review the role of apoptosis in renal injury, the potential molecular targets of therapeutic intervention, the therapeutic weapons to modulate the activity of these targets and the few examples of therapeutic intervention on apoptosis, with emphasis in acute renal failure.
Export Options
About this article
Cite this article as:
Lorz C., Benito-Martin A., Justo P., Sanz B. A., Sanchez-Nino D. M., Santamaria B., Egido J. and Ortiz A., Modulation of Renal Tubular Cell Survival: Where is the Evidence?, Current Medicinal Chemistry 2006; 13 (4) . https://dx.doi.org/10.2174/092986706775527956
DOI https://dx.doi.org/10.2174/092986706775527956 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Unraveling Progesterone-Induced Molecular Mechanisms in Physiological and Pathological Conditions
Current Clinical Pharmacology Thymulin: An Emerging Anti-Inflammatory Molecule
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Recent Advances in Cancer Therapy: An Overview
Current Pharmaceutical Design Subject Index To Volume 2
Current Nutrition & Food Science HDAC Inhibitors as Novel Anti-Cancer Therapeutics
Recent Patents on Anti-Cancer Drug Discovery Roles of IL-6-gp130 Signaling in Vascular Inflammation
Current Cardiology Reviews 2-Arylindoles: A Privileged Molecular Scaffold with Potent, Broad-Ranging Pharmacological Activity
Current Medicinal Chemistry Non-programmed Versus Programmed Aging Paradigm
Current Aging Science Growth Differentiation Factor-15 as a Biomarker of Obese Pre-diabetes and Type 2 Diabetes Mellitus in Indian Subjects: A Case-control Study
Current Diabetes Reviews Radiolabelled Regulatory Peptides for Imaging and Therapy
Anti-Cancer Agents in Medicinal Chemistry Designing Novel Therapies Against Sarcomas in the Era of Personalized Medicine and Economic Crisis
Current Pharmaceutical Design Metabolic Changes in Cancer Patients
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Drugs From the Sea: Conotoxins as Drug Leads for Neuropathic Pain and Other Neurological Conditions
Mini-Reviews in Medicinal Chemistry Gene/Cell Therapy Approaches for Immune Dysregulation Polyendocrinopathy Enteropathy X-Linked Syndrome
Current Gene Therapy The Evaluation and Utilization of Marine-derived Bioactive Compounds with Anti-obesity Effect
Current Medicinal Chemistry Genetics and Genomics of Hepatic Acute Phase Reactants: A Mini-Review
Inflammation & Allergy - Drug Targets (Discontinued) Pathophysiology and Treatment of Nonfamilial Hyperparathyroidism
Recent Patents on CNS Drug Discovery (Discontinued) Bisphenol A as a Factor in the Mosaic of Autoimmunity
Endocrine, Metabolic & Immune Disorders - Drug Targets Monitoring Molecular, Functional and Morphologic Aspects of Bone Metastases Using Non-Invasive Imaging
Current Pharmaceutical Biotechnology Immunomodulatory Properties of Thalidomide Analogs: Pomalidomide and Lenalidomide, Experimental and Therapeutic Applications
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery